binding affinity News and Research

RSS
Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

Bioactive compounds derived from Ganoderma lucidum exhibit anti-SARS-CoV-2 activity

Bioactive compounds derived from Ganoderma lucidum exhibit anti-SARS-CoV-2 activity

Researchers computationally design immunogens to elicit antibodies against different SARS-CoV-2 variants

Researchers computationally design immunogens to elicit antibodies against different SARS-CoV-2 variants

Q-LAAD: a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2

Q-LAAD: a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2

Omicron BA.1 breakthrough infection in vaccinated individuals recall memory B cells to confer immunity

Omicron BA.1 breakthrough infection in vaccinated individuals recall memory B cells to confer immunity

DNA nets effectively target the spike protein and detect COVID-19 virus at very low levels

DNA nets effectively target the spike protein and detect COVID-19 virus at very low levels

Deep mutational scanning for SARS-CoV-2 Omicron BA.1 and BA.2 subvariants

Deep mutational scanning for SARS-CoV-2 Omicron BA.1 and BA.2 subvariants

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

Molecular engineered low-cost highly effective RBD-based COVID vaccine

Molecular engineered low-cost highly effective RBD-based COVID vaccine

Lab experiments add further evidence to the bradykinin storm theory of COVID-19’s viral pathogenesis

Lab experiments add further evidence to the bradykinin storm theory of COVID-19’s viral pathogenesis

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

Development of improved monoclonal antibodies against SARS-CoV-2

Development of improved monoclonal antibodies against SARS-CoV-2

What is the impact of COVID-19 treatments targeting intracellular Neu1?

What is the impact of COVID-19 treatments targeting intracellular Neu1?

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

Scientists observe how SARS-CoV-2 protein dismantles critical immunity pathway

Scientists observe how SARS-CoV-2 protein dismantles critical immunity pathway

The use of AlphaFold2-enabled molecular docking simulations to predict protein-ligand interactions for antibiotic drug discovery

The use of AlphaFold2-enabled molecular docking simulations to predict protein-ligand interactions for antibiotic drug discovery

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

N501Y mutation and SARS-CoV-2 spike protein-angiotensin-converting enzyme-2 binding

N501Y mutation and SARS-CoV-2 spike protein-angiotensin-converting enzyme-2 binding

The effects of amino acid substitutions on the affinity of the SARS-CoV-2 spike RBD to the human receptor hACE2

The effects of amino acid substitutions on the affinity of the SARS-CoV-2 spike RBD to the human receptor hACE2